Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

被引：3
|
作者：
Gouda, M. A. [1 ]
Hu, M. I. [2 ]
Cabanillas, M. E. [2 ]
Wu, J. [3 ,4 ]
Meric-Bernstam, F. [1 ]
Subbiah, V. [1 ,5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA
[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA
[5] Sarah Cannon Res Inst, Early Phase Drug Dev, Nashville, TN 37203 USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷 / 10期
基金：
美国国家卫生研究院;
关键词：
CACHEXIA; PATHWAY;
D O I：
10.1016/j.annonc.2023.07.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：946 / 948
页数：3
相关论文
共 50 条
  • [21] RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions
    Hamidi, Sarah
    Hu, Mimi I.
    ANNALES D ENDOCRINOLOGIE, 2024, 85 (02) : 118 - 126
  • [22] A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
    Drilon, Alexander E.
    Subbiah, Vivek
    Oxnard, Geoffrey R.
    Bauer, Todd Michael
    Velcheti, Vamsidhar
    Lakhani, Nehal J.
    Besse, Benjamin
    Park, Keunchil
    Patel, Jyoti D.
    Cabanillas, Maria E.
    Johnson, Melissa Lynne
    Reckamp, Karen L.
    Boni, Valentina
    Loong, Herbert H. F.
    Schlumberger, Martin
    Solomon, Ben
    Cruickshank, Scott
    Rothenberg, Stephen M.
    Shah, Manisha H.
    Wirth, Lori J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
    Roskoski, Robert, Jr.
    Sadeghi-Nejad, Abdollah
    PHARMACOLOGICAL RESEARCH, 2018, 128 : 1 - 17
  • [24] A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.
    DuBois, Steven G.
    Albert, Catherine Michelle
    Mascarenhas, Leo
    Laetsch, Theodore Willis
    van Tilburg, Cornelis Martinus
    Potter, Samara L.
    Turpin, Brian
    Bender, Julia Lynne Glade
    Spunt, Sheri L.
    Hladun, Raquel
    Casanova, Michela
    Ziegler, David Simon
    Morgenstern, Daniel A.
    Eary, Todd
    Ibabekci, Shannon
    Qamoos, Hope
    Rothenberg, Stephen M.
    Cox, Michael Craig
    Balis, Frank M.
    Pappo, Alberto S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Molecular and pathological patterns of treatment failure in patients treated by RET selective inhibitors for metastatic medullary thyroid carcinoma
    Hadoux, J.
    Al Ghuzlan, A.
    Lamartina, L.
    Attard, M.
    Scoazec, J-Y.
    Hartl, D. M.
    Aldea, M.
    Friboulet, L.
    Italiano, A.
    Besse, B.
    Lacroix, L.
    Baudin, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1297 - S1297
  • [26] BLU-667 is a potent and highly selective RET inhibitor being developed for RET-driven cancers
    Rahal, Rami
    Maynard, Michelle
    Hu, Wei
    Brubaker, Jason
    Cao, Qiongfang
    Kim, Joseph L.
    Sheets, Michael P.
    Wilson, Douglas P.
    Wilson, Kevin J.
    DiPietro, Lucian
    Fleming, Paul
    LaBranche, Timothy P.
    Wolf, Beni
    Guzi, Timothy
    Lengauer, Christoph
    Evans, Erica K.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [27] Novel therapeutic agents for RET-driven cancers, which is highly potent and selective inhibitor to RET kinase
    Li, Hua
    Jo, SeoHyun
    Do, Woomi
    Kim, Hyunkyung
    Kim, Hwan
    Seo, Kyung-ah
    Oh, Ji-hoon
    Choi, Jieun
    Ahn, Jaeyoung
    Son, Jung Beom
    Kim, Nam Doo
    CANCER RESEARCH, 2019, 79 (13)
  • [28] Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.
    Taylor, Matthew H.
    Gainor, Justin F.
    Hu, Mimi I-Nan
    Zhu, Viola Weijia
    Lopes, Gilberto
    Leboulleux, Sophie
    Brose, Marcia S.
    Schuler, Martin H.
    Bowles, Daniel W.
    Kim, Dong-Wan
    Baik, Christina S.
    Garralda, Elena
    Lin, Chia-Chi
    Adkins, Douglas
    Sarker, Debashis
    Curigliano, Giuseppe
    Zhang, Hui
    Clifford, Corinne
    Turner, Christopher D.
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [29] Molecular characterization of primary and secondary resistance to RET inhibitors in patients with advanced NSCLC and RET fusions
    Marinello, A.
    Vasseur, D.
    Conci, N.
    Lindsay, C.
    Metro, G.
    Ferrara, R.
    Eisert, A.
    Citarella, F.
    Fallet, V.
    Audugier-Valette, C.
    Cousin, S.
    Tabbo, F.
    Russo, A.
    Blanco, A. Calles
    Gomez, P. Iranzo
    Tagliamento, M.
    Mezquita, L.
    Ponce, S.
    Besse, B.
    Aldea, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S26 - S26
  • [30] Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC
    Marinello, A.
    Vasseur, D.
    Conci, N.
    Fallet, V.
    Audigier-Valette, C.
    Cousin, S.
    Tabbo, F.
    Guisier, F.
    Russo, A.
    Blanco, A. Calles
    Metro, G.
    Massa, G.
    Citarella, F.
    Eisert, A. K.
    Gomez, P. Iranzo
    Tagliamento, M.
    Mezquita, L.
    Lindsay, C.
    Ponce, S.
    Aldea, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1013 - S1014
12345